Literature DB >> 3722365

Evaluation of avian-human reassortant influenza A/Washington/897/80 x A/Pintail/119/79 virus in monkeys and adult volunteers.

M L Clements, M H Snyder, A J Buckler-White, E L Tierney, W T London, B R Murphy.   

Abstract

A reassortant influenza A virus was produced by mating an avian influenza A/Pintail/Alberta/119/79 (H4N6) virus with wild-type human influenza A/Washington/897/80 (H3N2) virus. The avian-human influenza A reassortant virus contained the genes coding for the hemagglutinin and neuraminidase surface antigens of the human influenza wild-type virus and the six other RNA segments (internal genes) of the avian influenza A virus donor. In the lower respiratory tract of squirrel monkeys, this avian-human influenza reassortant virus, like its avian influenza A parent virus, was restricted approximately 100-fold in replication compared with the wild-type human influenza A virus. Despite this restriction of replication, infection of monkeys with the avian-human influenza A reassortant virus induced resistance to wild-type human influenza A virus challenge. In comparison with the wild-type human influenza A virus, the avian-human influenza A reassortant was also fully attenuated when 10(5.5) to 10(7.5) 50% tissue culture infective doses were administered to susceptible adult volunteers. Attenuation was indicated by a more than 300-fold reduction in virus shedding and lack of reactogenicity. The reassortant virus did not spread to susceptible contacts and could not be isolated from the blood or stools of infected adults. The 50% human infectious dose was 10(6.2) 50% tissue culture infective dose, indicating that this reassortant virus is only slightly less infectious for adults than a similarly derived avian-human influenza A/Washington/80 X A/Mallard/78 reassortant virus. These findings suggest that the avian influenza A/Pintail/79 virus may be a satisfactory donor of attenuating genes for production of live, attenuated avian-human influenza A reassortant virus vaccines.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3722365      PMCID: PMC268829          DOI: 10.1128/jcm.24.1.47-51.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  13 in total

1.  Determination of influenzavirus neuraminidase inhibition titres.

Authors:  D D Richman; B R Murphy; W L Cline; D W Alling
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

2.  Influenzavirus neuraminidase and neuraminidase-inhibition test procedures.

Authors:  M Aymard-Henry; M T Coleman; W R Dowdle; W G Laver; G C Schild; R G Webster
Journal:  Bull World Health Organ       Date:  1973       Impact factor: 9.408

3.  Dose response of influenza A/Washington/897/80 (H3N2) cold-adapted reassortant virus in adult volunteers.

Authors:  M L Clements; R F Betts; H F Maassab; B R Murphy
Journal:  J Infect Dis       Date:  1984-05       Impact factor: 5.226

4.  Genetic relatedness of the gene which codes for the nonstructural (NS) protein of different influenza A strains.

Authors:  C Scholtissek; V von Hoyningen-Huene
Journal:  Virology       Date:  1980-04-15       Impact factor: 3.616

5.  Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses.

Authors:  B R Murphy; M A Phelan; D L Nelson; R Yarchoan; E L Tierney; D W Alling; R M Chanock
Journal:  J Clin Microbiol       Date:  1981-03       Impact factor: 5.948

6.  Temperature-sensitive mutants of influenza virus. 3. Further characterization of the ts-1(E) influenza A recombinant (H3N2) virus in man.

Authors:  B R Murphy; E G Chalhub; S R Nusinoff; J Kasel; R M Chanock
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

7.  Avian-human reassortant influenza A viruses derived by mating avian and human influenza A viruses.

Authors:  B R Murphy; A J Buckler-White; W T London; J Harper; E L Tierney; N T Miller; L J Reck; R M Chanock; V S Hinshaw
Journal:  J Infect Dis       Date:  1984-12       Impact factor: 5.226

8.  Reassortant virus derived from avian and human influenza A viruses is attenuated and immunogenic in monkeys.

Authors:  B R Murphy; D L Sly; E L Tierney; N T Hosier; J G Massicot; W T London; R M Chanock; R G Webster; V S Hinshaw
Journal:  Science       Date:  1982-12-24       Impact factor: 47.728

9.  Evaluation of live avian-human reassortant influenza A H3N2 and H1N1 virus vaccines in seronegative adult volunteers.

Authors:  M H Snyder; M L Clements; R F Betts; R Dolin; A J Buckler-White; E L Tierney; B R Murphy
Journal:  J Clin Microbiol       Date:  1986-05       Impact factor: 5.948

10.  Evaluation of three strains of influenza A virus in humans and in owl, cebus, and squirrel monkeys.

Authors:  B R Murphy; D L Sly; N T Hosier; W T London; R M Chanock
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

View more
  14 in total

1.  Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles.

Authors:  N L Davis; I J Caley; K W Brown; M R Betts; D M Irlbeck; K M McGrath; M J Connell; D C Montefiori; J A Frelinger; R Swanstrom; P R Johnson; R E Johnston
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study.

Authors:  Matthew J Memoli; Lindsay Czajkowski; Susan Reed; Rani Athota; Tyler Bristol; Kathleen Proudfoot; Sarah Fargis; Matthew Stein; Rebecca L Dunfee; Pamela A Shaw; Richard T Davey; Jeffery K Taubenberger
Journal:  Clin Infect Dis       Date:  2014-11-20       Impact factor: 9.079

3.  Comparison of the virologic and immunologic responses of volunteers to live avian-human influenza A H3N2 reassortant virus vaccines derived from two different avian influenza virus donors.

Authors:  M L Clements; S D Sears; K Christina; B R Murphy; M H Snyder
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

4.  The avian influenza virus nucleoprotein gene and a specific constellation of avian and human virus polymerase genes each specify attenuation of avian-human influenza A/Pintail/79 reassortant viruses for monkeys.

Authors:  M H Snyder; A J Buckler-White; W T London; E L Tierney; B R Murphy
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

Review 5.  The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893-2014.

Authors:  A Sally Davis; Jeffery K Taubenberger; Mike Bray
Journal:  Antiviral Res       Date:  2015-03-05       Impact factor: 5.970

6.  Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone ® in rhesus macaques.

Authors:  Timothy D Carroll; Shannon R Matzinger; Mario Barro; Linda Fritts; Michael B McChesney; Christopher J Miller; Robert E Johnston
Journal:  Vaccine       Date:  2010-11-25       Impact factor: 3.641

7.  Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.

Authors:  Joshua M DiNapoli; Lijuan Yang; Amorsolo Suguitan; Subbiah Elankumaran; David W Dorward; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

8.  Comparison by studies in squirrel monkeys, chimpanzees, and adult humans of avian-human influenza A virus reassortants derived from different avian influenza virus donors.

Authors:  M H Snyder; M L Clements; D Herrington; W T London; E L Tierney; B R Murphy
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

Review 9.  The pathology of influenza virus infections.

Authors:  Jeffery K Taubenberger; David M Morens
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

10.  Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong.

Authors:  D L Suarez; M L Perdue; N Cox; T Rowe; C Bender; J Huang; D E Swayne
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.